Enveda
Enveda is a pioneering biotech company dedicated to decoding nature’s chemical code using AI and advanced data science. Their mission is to accelerate drug discovery by organizing, translating, and applying the vast, largely unexplored natural chemical space. By building the world’s largest searchable library of plant-derived molecules and developing foundation models like PRISM, Enveda aims to unlock the potential of natural compounds for human and planetary health, transforming how medicines are discovered and understood.
Industries
Nr. of Employees
medium (51-250)
Enveda
Products
Oral first-in-class anti-inflammatory small-molecule (early clinical candidate)
Orally administered novel small-molecule anti-inflammatory candidate progressed into Phase 1 clinical testing following preclinical efficacy and safety evaluations.
Gut-preferred oral small-molecule candidate for inflammatory bowel disease (IND-enabling)
Gut-targeted small molecule designed for preferential gastrointestinal exposure with completed IND-enabling studies and planned Phase 1 progression.
Oral small-molecule obesity candidate (IND-enabling)
First-in-class oral small molecule with a hormone-mimetic mechanism that has demonstrated preclinical efficacy and safety supportive of clinical translation.
Portfolio of development-stage natural-product-derived small-molecule programs
A pipeline of multiple development candidates and optimization-stage programs across inflammatory, fibrotic, neurological, and metabolic indications discovered from natural-product libraries and advanced through optimization and IND-enabling activities.
Oral first-in-class anti-inflammatory small-molecule (early clinical candidate)
Orally administered novel small-molecule anti-inflammatory candidate progressed into Phase 1 clinical testing following preclinical efficacy and safety evaluations.
Gut-preferred oral small-molecule candidate for inflammatory bowel disease (IND-enabling)
Gut-targeted small molecule designed for preferential gastrointestinal exposure with completed IND-enabling studies and planned Phase 1 progression.
Oral small-molecule obesity candidate (IND-enabling)
First-in-class oral small molecule with a hormone-mimetic mechanism that has demonstrated preclinical efficacy and safety supportive of clinical translation.
Portfolio of development-stage natural-product-derived small-molecule programs
A pipeline of multiple development candidates and optimization-stage programs across inflammatory, fibrotic, neurological, and metabolic indications discovered from natural-product libraries and advanced through optimization and IND-enabling activities.
Services
Integrated discovery platform combining high-throughput LC-MS/MS profiling, a large searchable library of natural samples, and machine-learning models trained on public and proprietary spectra to identify, prioritize, and annotate bioactive molecules from complex extracts.
Curated, computable database of traditional plant uses and scientific literature integrated with phytochemical and spectral data to rank plant and compound hypotheses for targeted screening.
Strategic collaborations with philanthropic and industry partners to advance discovery programs focused on priority global-health indications using natural-product discovery approaches and shared infrastructure.
Integrated discovery platform combining high-throughput LC-MS/MS profiling, a large searchable library of natural samples, and machine-learning models trained on public and proprietary spectra to identify, prioritize, and annotate bioactive molecules from complex extracts.
Curated, computable database of traditional plant uses and scientific literature integrated with phytochemical and spectral data to rank plant and compound hypotheses for targeted screening.
Strategic collaborations with philanthropic and industry partners to advance discovery programs focused on priority global-health indications using natural-product discovery approaches and shared infrastructure.
Expertise Areas
- Foundation models and self-supervised learning for metabolomics
- Mass-spectrometry-driven natural product discovery
- Large-scale MS/MS dataset assembly and curation
- High-throughput phenotypic and pathway screening
Key Technologies
- Tandem mass spectrometry (LC-MS/MS)
- Self-supervised transformer models for spectra
- Masked peak modeling (spectral masking)
- Spectral embeddings / representation learning
News & Updates
Enveda has raised $130 million to advance its AI-driven drug discovery platform, aiming to transform how medicines are discovered by exploring natural compounds and biological pathways.
Enveda has been recognized as one of America's Best Startup Employers in 2025, highlighting its innovative culture and growth in the biotech industry.
Enveda is listed among America’s Greatest Startup Workplaces in 2025, emphasizing its commitment to a positive work environment and impactful mission.
Enveda secured $55 million in funding to leverage ancient medicinal knowledge and AI technology to discover new drugs from natural sources.
Enveda is focused on translating the complex chemistry of life into effective medicines, utilizing AI to unlock the potential of natural compounds.
Recognized as a top startup employer in America for 2025, based on employer reputation, employee satisfaction, and growth.
Enveda has raised $130 million to advance its AI-driven drug discovery platform, aiming to transform how medicines are discovered by exploring natural compounds and biological pathways.
Enveda has been recognized as one of America's Best Startup Employers in 2025, highlighting its innovative culture and growth in the biotech industry.
Enveda is listed among America’s Greatest Startup Workplaces in 2025, emphasizing its commitment to a positive work environment and impactful mission.
Enveda secured $55 million in funding to leverage ancient medicinal knowledge and AI technology to discover new drugs from natural sources.
Enveda is focused on translating the complex chemistry of life into effective medicines, utilizing AI to unlock the potential of natural compounds.
Recognized as a top startup employer in America for 2025, based on employer reputation, employee satisfaction, and growth.